XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenues:    
Research and development revenue $ 460,520 $ 315,372
Costs and expenses:    
Costs of research and development revenue 390,762 278,182
Research and development 1,808,098 755,453
General and administrative 1,554,007 1,653,392
Foreign currency exchange loss (gain), net 28,272 10,867
Total costs and expenses 3,781,139 2,697,894
Loss from operations (3,320,619) (2,382,522)
Interest income 25,670 168,383
Net loss $ (3,294,949) $ (2,214,139)
Basic and diluted net loss per common share (in dollars per share) $ (0.12) $ (0.08)
Basic and diluted weighted-average common shares outstanding (in shares) 27,533,268 27,452,490